The strong correlation between MED18 expression and cryptic exon splicing levels indicated that by targeting the mediator complex, the ‘hazardous’ TP53 isoforms could potentially be turned into tumor-suppressing isoforms, which may offer an alternative approach for targeting aberrant TP53 in MM. Here, MED18 is linked to Miyoshi myopathy.